

ENQUÊTE PDV / PrEP



E Cua, P Puglièse, C Etienne, B Provost Keller, L Fredouille

High Discontinuation of Pre-Exposure Prophylaxis Within Six Months of Initiation

Chelsea L. Shover, PhD(c)^{1,2}; Marjan Javanbakht, PhD, MPH¹; Steven Shoptaw, PhD³; Robert K. Bolan, MD ²; Pamina M. Gorbach, MHS, DrPH¹

1. Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles; 2. Los Angeles LGBT Center;

3. Department of Family Medicine, UCLA

Outcome definitions

Active: Patient was prescribed TDF/FTC at the Center within the past 120 days.

Discontinued: Patient was most recently prescribed TDF/FTC at the Center more than 120 days ago, and has had at least one medical visit since receiving last PrEP prescription.

Lost to Follow-up: Patient was most recently prescribed TDF/FTC at the Center more than 120 days ago, and has had no medical visits since receiving last PrEP prescription.


Seroconversion: Development of HIV antibodies, detectable in blood, after exposure to HIV. Measured as date of first HIV positive test result.

L Chelsea, CROI 2018

At the end of the analysis period, 47% (n = 809) of patients who started PrEP were active, 37% had discontinued, and 16% were lost to follow-up.

FR : jeunes et pas d'assurance


Figure 3. PrEP discontinuation by type of insurance (n=1,715)



PrEP Implementation and Persistence in a County Health Department in Atlanta, GA

Charlotte-Paige Rolle MD MPH¹; Udodirim Onwubiko MBBS MPH²; Jennifer Jo MD¹;
Anandi N. Sheth MD MSc¹; Colleen F. Kelley MD MPH¹; David P. Holland MD MHS^{1, 2}

Figure 1. The PrEP Care Cascade at the FBCOH PrEP clinic (October 2015-March 2017)



- As of March 2017, 201 clients started PrEP, 88% were male, 65% were black, 69% were insured, 72% were MSM, 78% reported inconsistent condom use, and 80% had a prior STI




Figure 2. HIV incidence following PrEP discontinuation




Table 2. Participants with HIV infection

Case	Duration on PrEP	Stop reason	Days from PrEP stop to HIV detection	Age at diagnosis	Viral load at diagnosis	CD4 count at diagnosis
1	10 months	Temporary stop due to expiration of health card	56	27 years	247 000 copies/ml ³	699 cells/ml ³
2	2 months	Side effects including diarrhea	107	25 years	103 000 copies/ml ³	430 cells/ml ³
3	12 months	Personal decision	117	26 years	65 885 copies/ml ³	440 cells/ml ³

IPERGAY n=42

CONSULTATION PrEP

Sept 2013

Oct 2015

Jan 2016

Sept 2016

N=100

Fév 2018

N=500



Nice



+ CH de Grasse et CH de Cannes



Requête nadis : FA depuis 01/12/2015

1

- 454 recours pour PrEP

Requête nadis : FA depuis 01/12/2015

1

- 454 recours pour PrEP

2

- PDV depuis > 6 mois : N = 118 (26 %)
- Relecture des dossiers



Requête nadis : FA depuis 01/12/2015

1

- 454 recours pour PrEP

2

- PDV depuis > 6 mois : N = 118 (26 %)
- Relecture des dossiers



3

- **PDV = 47 (10,3 %)**



Requête nadis : FA depuis 01/12/2015

1

- 454 recours pour PrEP

2

- PDV depuis > 6 mois : N = 118 (26 %)
- Relecture des dossiers



3

- **PDV = 47 (10,3 %)**




4

- **PDV après initiation = 20 (4,4 %)**



PDV, N = 47



N = 18 / 33 PDV précoces (54 %) considérés à risque « élevé »

Discussion

- Sous ou sur estimation des PDV ?
- PrEPeurs responsables !
- PDV avant M1:
 - Découragés par procédure ?
 - Désintérêt crainte des effets secondaires après consultation initiale ?
- A confirmer sur le long terme
- Développer système d'alerte PDV et « navigateur » pour TASP et PrEP
- Analyser les facteurs de risque des PDVs
- Importance d'un outil de suivi commun